LLY

994.12

+0.59%↑

JNJ

242.44

+0.88%↑

ABBV

225.42

-1.97%↓

NVS

160.81

+0.66%↑

AZN

192.56

-0.93%↓

LLY

994.12

+0.59%↑

JNJ

242.44

+0.88%↑

ABBV

225.42

-1.97%↓

NVS

160.81

+0.66%↑

AZN

192.56

-0.93%↓

LLY

994.12

+0.59%↑

JNJ

242.44

+0.88%↑

ABBV

225.42

-1.97%↓

NVS

160.81

+0.66%↑

AZN

192.56

-0.93%↓

LLY

994.12

+0.59%↑

JNJ

242.44

+0.88%↑

ABBV

225.42

-1.97%↓

NVS

160.81

+0.66%↑

AZN

192.56

-0.93%↓

LLY

994.12

+0.59%↑

JNJ

242.44

+0.88%↑

ABBV

225.42

-1.97%↓

NVS

160.81

+0.66%↑

AZN

192.56

-0.93%↓

Kodu・Aktsiate loetelu・Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Avatud

SektorTervishoid

60.52 44.44

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

41.9

Max

61.99

Põhinäitajad
By Trading Economics
Sissetulek	-14M -105M
Kasumimarginaal	-867.293
Töötajad	316
EBITDA	-15M -104M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+33.33% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	11. mai 2026

Turustatistika
By TradingEconomics
Turukapital	-13M 3.3B
Eelmine avamishind	16.08
Eelmine sulgemishind	60.52

Uudiste sentiment

By Acuity

50%

128 / 351 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

34.81 / 38.24 Toetus ja vastupanu

Xenon Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

6. märts 2026, 19:32 UTC

Omandamised, ülevõtmised, äriostud

Diana Shipping Increases Offer to Acquire Genco -- Update

8. märts 2026, 23:47 UTC

Market Talk

Uudisväärsed sündmused

Global Equities Roundup: Market Talk

8. märts 2026, 23:47 UTC

Market Talk

Uudisväärsed sündmused

Nikkei May Fall on Higher Energy Prices, Signs of U.S. Econ Weakness -- Market Talk

8. märts 2026, 23:46 UTC

Market Talk

Uudisväärsed sündmused

Gold Falls Amid Dollar's Strength -- Market Talk

8. märts 2026, 23:34 UTC

Market Talk

Uudisväärsed sündmused

Oil Futures Surge Above $100/bbl Amid Growing Middle East Conflict -- Market Talk

8. märts 2026, 23:08 UTC

Uudisväärsed sündmused

Front-month WTI Crude Futures Jump 16.6%, Front-Month Brent Crude Futures Climb 15.2%

8. märts 2026, 23:05 UTC

Uudisväärsed sündmused

Front-month Crude Oil Futures Surge Amid Rising Middle East Conflict

8. märts 2026, 22:37 UTC

Uudisväärsed sündmused

The Long-Feared Persian Gulf Oil Squeeze Is Upon -2-

8. märts 2026, 22:37 UTC

Uudisväärsed sündmused

The Long-Feared Persian Gulf Oil Squeeze Is Upon Us -- WSJ

7. märts 2026, 02:30 UTC

Uudisväärsed sündmused

Iran War Is Kicking India When It's Already Down -- Barrons.com

6. märts 2026, 22:26 UTC

Uudisväärsed sündmused

Why $100 Oil Is Now in Sight. Who Wins, Who Loses. -- Barrons.com

6. märts 2026, 22:07 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Boeing Says Spirit Acquisition Will Help Improve Safety -- Market Talk

6. märts 2026, 22:03 UTC

Market Talk

Global Equities Roundup: Market Talk

6. märts 2026, 22:03 UTC

Market Talk

Boeing CEO's Pay Nears $24 Million During Recovery Phase -- Market Talk

6. märts 2026, 21:50 UTC

Market Talk

Uudisväärsed sündmused

Financial Services Roundup: Market Talk

6. märts 2026, 21:37 UTC

Tulu

Salesforce Stock Might Not Be an AI Loser After All -- Barrons.com

6. märts 2026, 21:25 UTC

Uudisväärsed sündmused

How The Iran War Impacts Ukraine. -- Barrons.com

6. märts 2026, 21:17 UTC

Tulu

Burlington Stores' Strong Year Should Lift the Stock. What Comes Next. -- Barrons.com

6. märts 2026, 20:50 UTC

Tulu

Marvell Stock Pops 20%. Semiconductor Earnings Show AI Demand Is Strong. -- Barrons.com

6. märts 2026, 20:46 UTC

Tulu

Nike Reports $300 Million Pretax Charge Related to Job Cuts -- Barrons.com

6. märts 2026, 20:31 UTC

Uudisväärsed sündmused

Oil Prices Soar Past $90. Trump Demands 'Unconditional Surrender' From Iran -- and Kuwait Cut Production. -- Barrons.com

6. märts 2026, 20:18 UTC

Market Talk

Oil Makes Record Weekly Gains As Strait of Hormuz Stays Shut -- Market Talk

6. märts 2026, 20:12 UTC

Market Talk

Uudisväärsed sündmused

U.S. Natural Gas Futures Gain on Global Energy Turmoil -- Market Talk

6. märts 2026, 19:10 UTC

Market Talk

Uudisväärsed sündmused

$150 Oil Seen As Realistic If Hormuz Closure Lasts -- Market Talk

6. märts 2026, 18:54 UTC

Market Talk

Fed's Hammack: Dollar Hasn't Lost Prime Status -- Market Talk

6. märts 2026, 18:44 UTC

Market Talk

Uudisväärsed sündmused

U.S. Oil Rig Count Increases By 4 to 411 -- Market Talk

6. märts 2026, 18:08 UTC

Tulu

Samsara Stock Jumps 16% After Earnings. Why the CEO Isn't Worried About AI. -- Barrons.com

6. märts 2026, 18:04 UTC

Tulu

Marvell Stock Surges on Earnings. It's Not Just a Custom AI Chip Story. -- Barrons.com

6. märts 2026, 18:04 UTC

Tulu

Samsara Stock Jumps 16% After Earnings. Why the CEO Isn't Worried About AI. -- Barrons.com

6. märts 2026, 17:49 UTC

Market Talk

AI-Driven Picks-And-Shovels Bet Comes With Risks -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Xenon Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

33.33% tõus

12 kuu keskmine prognoos

Keskmine 55.92 USD 33.33%

Kõrge 66 USD

Madal 44 USD

Põhineb 15 Wall Streeti analüütiku instrumendi Xenon Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

15 ratings

Osta

Hoia

Müü

Põhineb 15 analüütiku instrumendi Xenon Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

34.81 / 38.24Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

128 / 351 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.